Jesse Lomonaco, DO
Neuromusculoskeletal Medicine & OMM · Marlton, NJNPI 1750314274
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,051 and has fallen 95.9% since, to $43 in 2025.
Across 285 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$537
- Astellas Pharma US Inc$490
- Johnson & Johnson$310
- Kowa Pharmaceuticals America, Inc.$247
- Amarin Pharma, Inc.$209
- Amgen$189
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,10198%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $537 |
| Astellas Pharma US Inc | 31 | $490 |
| Johnson & Johnson | 22 | $310 |
| Kowa Pharmaceuticals America, Inc. | 17 | $247 |
| Amarin Pharma, Inc. | 15 | $209 |
| Amgen | 13 | $189 |
| Novartis | 11 | $162 |
| Eisai Inc. | 10 | $158 |
| Pfizer | 10 | $155 |
| Boehringer Ingelheim | 11 | $154 |
| AbbVie | 10 | $140 |
| Otsuka America Pharmaceutical, Inc. | 7 | $130 |
| GSK | 9 | $126 |
| Merck | 8 | $109 |
| Abbott | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $86 |
| Daiichi Sankyo Inc. | 6 | $77 |
| Lilly USA, LLC | 5 | $77 |
| Sumitomo Pharma America, Inc. | 5 | $77 |
| Exact Sciences | 4 | $75 |
| AstraZeneca | 5 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| E.r. Squibb & Sons, L.L.C. | 4 | $54 |
| Bayer | 3 | $51 |
| Corium, LLC | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| UCB, Inc. | 2 | $28 |
| Biogen | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Qiagen, LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Vivus LLC | 1 | $12 |
| Digestive Care, Inc. | 1 | $11 |
How this compares
Too few neuromusculoskeletal medicine & omm providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $27,146 |
| OzempicSemaglutide | 13 | $19,249 |
| XareltoRivaroxaban | 16 | $15,725 |
| MyrbetriqMirabegron | 18 | $11,524 |
| SantylCollagenase Clostridium Hist. | 19 | $6,120 |
| Potassium Chloride | 40 | $5,572 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $5,063 |
| Metoprolol Succinate | 88 | $1,040 |
| Rosuvastatin Calcium | 78 | $1,018 |
| Atorvastatin Calcium | 93 | $926 |
| Levothyroxine Sodium | 67 | $876 |
| SynthroidLevothyroxine Sodium | 13 | $869 |
| Allopurinol | 20 | $807 |
| Clonidine | 12 | $734 |
| Solifenacin Succinate | 11 | $633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $155 | $27,14655 claims |
| Novo NordiskOzempic | $537 | $19,24913 claims |
| Johnson & JohnsonXarelto | $310 | $15,72516 claims |
| Astellas Pharma US IncMyrbetriq | $490 | $11,52418 claims |
| AbbVieSynthroid | $140 | $86913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine & omm providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other neuromusculoskeletal medicine & omm in Marlton
- Mary SedarousNeptune$15K
- Boris FurmanManalapan$12K
- Abraham MorganoffWarren$2K
- Kirstin SanbornSewell$443
- John InfantolinoBrick$422
- Jeffrey FranceHolmdel$260
- Duncan CarpenterRidgewood$170
- Garren GebhardtMorristown$125
- Daniel ConteGarfield$72
- Chanakya BavishiStratford$23
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.